Fujirebio presented data on its Lumipulse G pTau217/β‑Amyloid 1‑42 plasma ratio test, positioning the assay to shorten diagnostic timelines for Alzheimer’s disease by providing accessible blood‑based biomarker readouts. The company claims high diagnostic performance that could move patients into care pathways earlier and reduce reliance on CSF assays or PET imaging. The test targets phosphorylated tau (pTau217) and an amyloid ratio that correlates with neuropathology; results could influence earlier therapeutic decision making and trial enrollment. Clinical adoption will depend on regulatory clearances, reimbursement pathways, and demonstrable real‑world impact on diagnostic workflows. Blood‑based biomarkers are rapidly shifting neurology diagnostics; Fujirebio’s assay joins competing platforms racing for clinical validation and payer acceptance.